C. Schuchardt, J. Zhang, H. Kulkarni, X. Chen, D. Müller, R. Baum
{"title":"使用177Lu-PSMA I&T和177Lu-PSMA-617放射治疗转移性去势抵抗性前列腺癌:安全性、生物分布和剂量学的比较","authors":"C. Schuchardt, J. Zhang, H. Kulkarni, X. Chen, D. Müller, R. Baum","doi":"10.1055/s-0043-1766153","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":281512,"journal":{"name":"61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin","volume":"107 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PSMA radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry\",\"authors\":\"C. Schuchardt, J. Zhang, H. Kulkarni, X. Chen, D. Müller, R. Baum\",\"doi\":\"10.1055/s-0043-1766153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":281512,\"journal\":{\"name\":\"61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin\",\"volume\":\"107 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0043-1766153\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"61. Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0043-1766153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PSMA radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry